Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.53 |
| ▸ | KLKB1 | P03952 | 17/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16246943 | 0.96 | GRM2 (0.56) | GRM2KLKB1DGAT1KDM4E | |
| SCHEMBL16246717 | 0.89 | KLKB1 (0.46) | KLKB1DGAT1 | |
| SCHEMBL17785281 | 0.89 | GRM2 (0.50) | GRM2KLKB1DGAT1KDM4E | |
| SCHEMBL21954007 | 0.85 | GRM2 (0.51) | GRM2KLKB1DGAT1KDM4E | |
| SCHEMBL16246993 | 0.82 | KLKB1 (0.59) | KLKB1DGAT1 | |
| SCHEMBL18617480 | 0.82 | DGAT1 (0.59) | GRM2KLKB1DGAT1KDM4E | |
| SCHEMBL21316083 | 0.81 | GRM2 (0.38) | GRM2KLKB1DGAT1 | |
| SCHEMBL17787079 | 0.81 | GRM2 (0.49) | GRM2KLKB1DGAT1KDM4E | |
| SCHEMBL16246800 | 0.81 | KLKB1 (0.47) | GRM2KLKB1 | |
| SCHEMBL16246817 | 0.81 | GRM2 (0.54) | GRM2KLKB1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3224256-A1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS, | Kalvista Pharmaceuticals Limited (GB) | 2017-10-04 | — | — | EP | disclosed |
| WO-2016083820-A1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS, | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-06-02 | — | — | WO | disclosed |